Key result
Neonova TEER achieves ~93% 1-year event-free survival in primary mitral regurgitation.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The [two]-year Neonova trial demonstrates the feasibility and safety of this novel device in a carefully selected primary-MR cohort… Ultimately, integration of a multidisciplinary heart-team approach in treating patients with severe MR remains the cornerstone of delivering high-quality transcathe...”
Highlights two-year durability of transcatheter edge-to-edge repair in high-risk mitral regurgitation, indicating expanding device options tailored to regional anatomical differences.
No abstract yet. The journal hasn't published one we can show.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) conducted an editorial in Symptomatic moderate-to-severe or severe primary mitral regurgitation (n=123). Neonova transcatheter edge-to-edge repair (TEER) system vs. Prespecified 60% performance goal (single-arm) was evaluated on 1-year event-free survival. The Neonova TEER system achieved 92.7% 1-year event-free survival and 95.4% MR ≤2+ with 4.1% mortality at 2 years in primary MR.
Synapse has enriched 10 related papers. Consider them for comparative context: